


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
+26.64%
+5.29%
-16.76%
+16.46%
-13.51%
MLTX
MoonLake Immunotherapeuti
$15.77
Risk Analysis

Earnings are forecast to decrease
MLTX Price Performance
$16.76 (-5.91%)
$13.4 (+17.69%)
$54.98 (-71.32%)
$39.71 (-60.29%)
Overall standing based on market and analyst consensus.
Hover over the category for more information
Earnings
Earnings
Rating
Rating
Momentum
Momentum

Has been gaining momentum
Activity
Activity
Future
Future

Earnings are forecast to decrease
![]()
MLTX Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
MLTX Street Sentiment is unimpressive and have negative views on the near-term outlook
MLTX has Extreme risk level
Risks Indicators

Beta greater than 1.0

High volatilty

Average key support and resistance price levels
Recent Upgrades and Downgrades
BUY
Date
Action
Rating
Firm
Jan 09, 2026
Upgrade
Buy
BTIG
Nov 21, 2025
Reiterate
Buy
HC Wainwright & Co.
Sep 30, 2025
Reiterate
Buy
Needham
MRK
Merck Company
121.41
+1.78%
SNY
Sanofi
46.01
-2.17%
LLY
Eli Lilly and
1040.00
+0.35%
INSM
Insmed
148.75
+1.77%
IFRX
InflaRx N.V.
0.86
+3.43%
What is MLTX current stock price?
What are MLTX stock strengths?
What is MLTX Risk Level?
What is MLTX market cap and volume?
What is MLTX current Stock IQ?
Should I buy MLTX stock right now?
Is MLTX a Strong Buy right now?
What does a 'Strong Buy' rating mean for MLTX?
What does a 'Strong Sell' rating mean for MLTX?
What factors influence MLTX's Stock IQ?
Join over 5,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+26.64%
+5.29%
-16.76%
+16.46%
-13.51%
MLTX
MoonLake Immunotherapeuti
Current Price
$15.77
Runners Also Watch
MRK
Merck Company
121.41
+1.78%
SNY
Sanofi
46.01
-2.17%
LLY
Eli Lilly and
1040.00
+0.35%
INSM
Insmed
148.75
+1.77%
IFRX
InflaRx N.V.
0.86
+3.43%

MLTX Price Performance
$16.76 (-5.91%)
$13.4 (+17.69%)
$54.98 (-71.32%)
$39.71 (-60.29%)
MLTX Analysts Opinion
Overall standing per market and analyst expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating
Momentum
Momentum

Has been gaining momentum
Activity
Activity
Future
Future

Earnings are forecast to decrease
![]()
MLTX Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
MLTX Street Sentiment is unimpressive and have negative views on the near-term outlook
MLTX has Extreme risk level
Risks Indicators

Beta greater than 1.0

High volatilty

Average key support and resistance price levels
Overall Wall Street Rating
BUY
Jan 09, 2026
Upgrade
Buy
BTIG
Nov 21, 2025
Reiterate
Buy
HC Wainwright & Co.
Sep 30, 2025
Reiterate
Buy
Needham
MLTX Stock IQ
Stock Insights
Risk Analysis

Earnings are forecast to decrease
MLTX Latest Analysis
Goldman Sachs Notes VELA-2 Failure Calls MoonLake Immunotherapeutics (MLTX) a High-Risk Play. We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. MoonLake Immunotherapeutics is the next stock on our list. TheFly reported on January 14 that Goldman Sachs downgraded MLTX to Sell from Neutral and set a price target of $10 up from $8. The firm noted that sonelokimabs advancement into Phase 3 for palmoplantar [….]
Mon Feb 2, 2026
MoonLake Announces FDA Fast Track Designation for Sonelokimab Palmoplantar Pustulosis (PPP) and Provides Details on Upcoming Investor Day. ZUG Switzerland February 2 2026 – MoonLake Immunotherapeutics (NASDAQ:MLTX) (MoonLake or the Company) a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases today announces that the FDA has granted Fast Track designation for sonelokimab for the treatment of moderate‑to‑severe PPP. MoonLake had submitted a req
Mon Feb 2, 2026
FIND US ON
Unlock the knowledge that 5,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
MLTX Stock trends
MLTX Stock performance
MLTX Stock analysis
MLTX investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.